Hetero Labs Ltd Vi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HETERO LABS LTD VI
HETERO LABS LTD VI has seven approved drugs.
Drugs and US Patents for Hetero Labs Ltd Vi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero Labs Ltd Vi | DECITABINE | decitabine | INJECTABLE;INTRAVENOUS | 215355-001 | May 10, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 215765-001 | Oct 15, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 215460-001 | Jun 14, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | METHOTREXATE SODIUM | methotrexate sodium | INJECTABLE;INJECTION | 219865-001 | Apr 30, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 217560-001 | Jun 16, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

